Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 4.06
ATRC's Cash to Debt is ranked higher than
76% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.78 vs. ATRC: 4.06 )
ATRC' s 10-Year Cash to Debt Range
Min: 1.42   Max: No Debt
Current: 4.06

Equity to Asset 0.65
ATRC's Equity to Asset is ranked higher than
73% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. ATRC: 0.65 )
ATRC' s 10-Year Equity to Asset Range
Min: -2.15   Max: 0.97
Current: 0.65

-2.15
0.97
F-Score: 4
Z-Score: 5.91
M-Score: 10.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -13.30
ATRC's Operating margin (%) is ranked higher than
56% of the 283 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.96 vs. ATRC: -13.30 )
ATRC' s 10-Year Operating margin (%) Range
Min: -15700   Max: -5.41
Current: -13.3

-15700
-5.41
Net-margin (%) -14.00
ATRC's Net-margin (%) is ranked higher than
57% of the 283 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.72 vs. ATRC: -14.00 )
ATRC' s 10-Year Net-margin (%) Range
Min: -17980   Max: -6.43
Current: -14

-17980
-6.43
ROE (%) -15.79
ATRC's ROE (%) is ranked higher than
57% of the 279 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. ATRC: -15.79 )
ATRC' s 10-Year ROE (%) Range
Min: -207.74   Max: -15.79
Current: -15.79

-207.74
-15.79
ROA (%) -10.24
ATRC's ROA (%) is ranked higher than
58% of the 286 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. ATRC: -10.24 )
ATRC' s 10-Year ROA (%) Range
Min: -175.33   Max: -10.24
Current: -10.24

-175.33
-10.24
ROC (Joel Greenblatt) (%) -150.35
ATRC's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 284 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.38 vs. ATRC: -150.35 )
ATRC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -194.92   Max: -32.05
Current: -150.35

-194.92
-32.05
Revenue Growth (%) 0.80
ATRC's Revenue Growth (%) is ranked higher than
65% of the 248 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. ATRC: 0.80 )
ATRC' s 10-Year Revenue Growth (%) Range
Min: -29.9   Max: 915.8
Current: 0.8

-29.9
915.8
EBITDA Growth (%) 120.70
ATRC's EBITDA Growth (%) is ranked higher than
99% of the 209 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.50 vs. ATRC: 120.70 )
ATRC' s 10-Year EBITDA Growth (%) Range
Min: -62.7   Max: 120.7
Current: 120.7

-62.7
120.7
EPS Growth (%) 30.80
ATRC's EPS Growth (%) is ranked higher than
90% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.80 vs. ATRC: 30.80 )
ATRC' s 10-Year EPS Growth (%) Range
Min: -45.4   Max: 36.3
Current: 30.8

-45.4
36.3
» ATRC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ATRC Guru Trades in Q1 2013

Jim Simons 83,500 sh (-30.82%)
» More
Q2 2013

ATRC Guru Trades in Q2 2013

Jim Simons 35,320 sh (-57.7%)
» More
Q3 2013

ATRC Guru Trades in Q3 2013

Jim Simons Sold Out
» More
Q4 2013

ATRC Guru Trades in Q4 2013

Jim Simons 31,700 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with ATRC



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.23
ATRC's P/B is ranked lower than
57% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. ATRC: 5.23 )
ATRC' s 10-Year P/B Range
Min: 0.64   Max: 14.1
Current: 5.23

0.64
14.1
P/S 4.08
ATRC's P/S is ranked lower than
58% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.63 vs. ATRC: 4.08 )
ATRC' s 10-Year P/S Range
Min: 0.27   Max: 5.53
Current: 4.08

0.27
5.53

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 163.10
ATRC's Price/Net Current Asset Value is ranked lower than
85% of the 114 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.40 vs. ATRC: 163.10 )
ATRC' s 10-Year Price/Net Current Asset Value Range
Min: 4.06   Max: 186.8
Current: 163.1

4.06
186.8
Price/Tangible Book 14.06
ATRC's Price/Tangible Book is ranked lower than
73% of the 227 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. ATRC: 14.06 )
ATRC' s 10-Year Price/Tangible Book Range
Min: 1.45   Max: 16.1
Current: 14.06

1.45
16.1
Price/DCF (Projected) 21.75
ATRC's Price/DCF (Projected) is ranked lower than
71% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.50 vs. ATRC: 21.75 )
ATRC' s 10-Year Price/DCF (Projected) Range
Min: 24.91   Max: 24.91
Current: 21.75

Price/Median PS Value 1.78
ATRC's Price/Median PS Value is ranked lower than
61% of the 264 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. ATRC: 1.78 )
ATRC' s 10-Year Price/Median PS Value Range
Min: 0.25   Max: 2.04
Current: 1.78

0.25
2.04
Forward Rate of Return (Yacktman) -1.28
ATRC's Forward Rate of Return (Yacktman) is ranked higher than
67% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.47 vs. ATRC: -1.28 )
ATRC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -197.4   Max: 93.7
Current: -1.28

-197.4
93.7

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:A5I.Germany
AtriCure, Inc., was incorporated in the State of Delaware as AtriCure, Inc. on October 31, 2000. It is a medical device company and engaged in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, in cardiac, or heart, tissue for the treatment of atrial fibrillation, and systems for the exclusion of the left atrial appendage. It has two primary product lines for the ablation of cardiac tissue. Its primary product line for the ablation of cardiac tissue is the AtriCure Synergy Ablation System ('Synergy System'), a bipolar ablation clamp system and related radiofrequency ('RF') ablation devices. It also offers a cryoablation product line, which features reusable and disposable cryoablation devices. Additionally, the Company offers the AtriClip Gillinov-Cosgrove Left Atrial Appendage System ('AtriClip System'), which is designed to safely and effectively exclude the left atrial appendage. Its products are utilized by cardiothoracic surgeons during concomitant open-heart surgical procedures and also during sole-therapy minimally invasive cardiac ablation procedures. During a concomitant open procedure, the surgeon ablates cardiac tissue and/or excludes the left atrial appendage, secondary, or concomitant, to a primary cardiac procedure such as a valve or coronary bypass. Additionally, cardiothoracic surgeons have adopted its products as a treatment alternative for AF patients who may be candidates for sole-therapy minimally invasive surgical procedures. Its Synergy System, which includes its Isolator Synergy clamps, a radiofrequency generator and related switchbox, is cleared by the FDA, for the treatment of patients with persistent and long-standing persistent AF during open-heart concomitant coronary artery bypass grafting and/or valve replacement or repair procedures. In the United States it primarily sells its products to medical centers through its direct sales force. AtriCure Europe, B.V., its wholly-owned subsidiary incorporated and based in the Netherlands, markets and sells its products throughout Europe, the Middle East and Africa, or EMEA, primarily through distributors, while in certain markets, such as Germany and the Benelux region, it sell directly to medical centers. Additionally, it sells its products to other international distributors, mainly in Asia, South America and Canada. The Company's competitors include Biosense Webster, Inc. (a subsidiary of Johnson & Johnson), St. Jude Medical, Inc., and Medtronic, Inc. Its products are medical devices and are subject to regulation by the FDA, as well as other federal and state regulatory bodies in the United States and comparable authorities in other countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide